C4U Corporation

July 21, 2023

C4U and Rege Nephro have entered into a non-exclusive agreement, granting Rege Nephro the right to manufacture and sell cells induced to differentiate from PKD1 gene knockout induced pluripotent stem cells (iPS cells). Rege Nephro uses CRISPR-Cas3 technology to produce such PKD1 gene knockout iPS cells, and their product will be used for the discovery of new therapeutic agents to cure Autosomal Dominant (overt) Multiple Cystic Kidney Disease (ADPKD).

July 13, 2023

The patent for the invention, “METHOD FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN METHOD," was issued by the Japan Patent Office on 23 June, 2023.
Patent registration number is 7301332.
This patent is matured from a divisional application of the Japanese Patent No. 6480647 issued in February 2019. Due to said patent, the claims and the scope of this patent become broader than the basic patent for the CRISPR-Cas3 system.
C4U anticipates that this patent will further strengthen the foundation of intellectual property rights with regard to CRISPR-Cas3 technology and further promote its application in a wide range of fields.

June 30, 2023

C4U has entered into a collaborative research and alliance agreement with Inplanta Innovations, Inc., the most capable and competent contract research company in the field of plant biotech in Japan, to promote a research and development for the application of CRISPR-Cas3 technology in the plant field.
C4U aims to widely deploy CRISPR-Cas3 genome editing technology as a platform technology, and this collaborative research and alliance agreement is an important part of that platform development.
Furthermore, C4U is looking forward to the possibility of contributing to social issues related to the global environment through the results of collaborative research and development with Inplanta Innovations in the future.

May 17, 2023

C4U Corporation has raised a total of 1.5 billion JPY (approximately $11 million at the then-effective exchange rate) for its Series B financing.
DCI Partners, Co., Ltd. who has been a lead investor since the Series A round in 2021, and other six investors including four new investors participated in this Series B round.
Since its establishment in March 2018, the accumulated funds have reached 2.6 billion JPY, and C4U plans to use the funds for further research and development of CRISPR-Cas3 system and its applications in a medical field, especially in vivo and ex vivo treatments.
In addition to the above, C4U is also seeking opportunities in any industrial fields.

March 15, 2023

Our researcher will give a poster presentation at the Keystone Symposia on Molecular and Cellular Biology "Precision Genome Engineering", in Whistler, Canada, from March 19-23, 2023.

What's new?